Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Merck has stocked up on data to support moving Keytruda up as a first-line therapy for head and neck squamous cell carcinoma.
An interim analysis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
